Physician profile
Ali Salah
NPI 1225056724
$1,536.12
in general payments reported to CMS, 2019-2025
14 companies · $41.11 in 2025
The $41.11 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $219 · 2021: $74.99 · 2022: $221 · 2023: $12.81 · 2024: $39.94 · 2025: $41.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $93.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $93.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $871.87 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $264.43 | 2019-2022 | |
| Amgen INC. | $88.36 | 2019-2020 | |
| United Therapeutics Corporation | $87.71 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.80 | 2019 | |
| Lantheus Medical Imaging, INC. | $33.71 | 2019 | |
| Pfizer INC. | $29.17 | 2019 | |
| Amarin Pharma, INC. | $23.96 | 2019-2021 | |
| Novo Nordisk INC | $21.78 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $19.30 | 2019 | |
| Lundbeck LLC | $16.37 | 2020 | |
| Portola Pharmaceuticals, LLC | $14.89 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.40 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Salah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.